Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes of Toujeo Compared to Commercially Available Basal Insulins for Initiation of Therapy in Insulin-naive Patients With Uncontrolled Type 2 Diabetes Mellitus
Brief Summary: Primary Objective:

Demonstrate clinical benefit of Toujeo in achieving individualized Healthcare Effectiveness Data and Information Set (HEDIS) glycated hemoglobin (HbA1c) targets (\<8% if age \>=65 years or with defined comorbidities or otherwise \<7%) at 6 months without documented symptomatic (Blood Glucose \<=70 mg/deciliter \[mg/dL\]) and/or severe hypoglycemia at any time of day from baseline to 6 months in uncontrolled insulin naive participants with type 2 diabetes initiating basal insulin therapy in a real world setting.

Secondary Objectives:

Compare Toujeo to other commercially available basal insulins at 6 months after initiating insulin therapy in a real world setting in terms of:

* Participant persistence with assigned basal insulin therapy.
* Risk of hypoglycemia including the incidence and rate of documented symptomatic and severe hypoglycemia.
* Changes in HbA1c, fasting plasma glucose, body weight
* Differences in participant and provider- reported outcomes (including Diabetes Treatment Satisfaction Questionnaire Status and Change Versions (DTSQs) and (DTSQc), Hypoglycemia Patient Questionnaire, and participant and provider reported Global Effectiveness Scale (GES).
* Healthcare resource utilization including hospitalizations and emergency department or other provider visits and healthcare costs.


Options:
A: Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine (HOE901) [Lantus], Drug: Glimepiride | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: human insulin [NPH] | Intervention Type: DRUG; Name: Insulin Glargine (HOE901) [Lantus]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: human insulin [NPH]; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin | Intervention Type: DRUG; Name: Insulin Glargine (HOE901)/NPH Insulin; Assigned to Arm(s): 1, 2
D: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine, 300 U/ml, Drug: Background Therapy | Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin glargine, 100 U/ml, Drug: Insulin detemir, Drug: Background Therapy | Intervention Type: DRUG; Name: Insulin glargine, 300 U/ml; Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: Insulin glargine, 100 U/ml; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: Insulin detemir; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: Background Therapy; Assigned to Arm(s): Standard of Care, Toujeo

Answer: D